Modified MVP R8 Flexible Region for Consistent Vault Particle Packaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Recombinant vault particles face challenges in consistent passenger molecule packaging due to unpredictable mINT fusion and limited passive packaging, which can disrupt vault structure formation and result in inefficient delivery of therapeutic proteins.
Innovation Solution
A modified MVP R8 protein with amino acid substitutions, additions, or deletions in its R8 flexible region is used, allowing for the insertion of passenger molecules without disrupting the vault structure, enabling consistent and efficient formation of recombinant vault particles capable of delivering therapeutic proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If mINT fusion packaging is used to package passenger molecules in vault particles, then passenger molecules can be delivered, but the packaging becomes unpredictable and inconsistent and may disrupt vault structure formation
Solution Approach 1:
The MVP protein is divided into functional segments, with the R8 domain identified as a specific packaging region. By targeting passenger molecules to this segmented region through fusion with the R8 domain rather than using mINT fusion, the patent achieves consistent and predictable packaging while maintaining vault structure formation.
Solution Approach 2:
The R8 domain of the MVP protein serves as an intermediary element that mediates between the passenger molecule and the vault structure. Fusion of passenger molecules to the R8 domain provides a reliable interface for packaging that does not disrupt vault assembly, resolving the inconsistency problem of mINT fusion.
2Adaptability or versatility
If passenger molecules are fused to the N-terminus of MVP, then they are located inside the vault at the waist, but this disrupts and prevents vault structure formation
Solution Approach 1:
Instead of fusing passenger molecules to the N-terminus of MVP, the patent targets the specific R8 domain located at the waist region. This local quality approach allows passenger molecules to be positioned inside the vault at the desired location without disrupting overall vault structure formation, as the R8 domain is a specialized region designed for this purpose.
Solution Approach 2:
The patent uses preliminary action by designing the R8 domain fusion construct before vault assembly occurs. The passenger molecule is pre-fused to the R8 domain, which then guides proper incorporation into the vault structure during assembly, preventing structural disruption that would occur with N-terminal fusion.
3Productivity
If passive packaging is used, then molecules can be packaged within the vault structure, but this is limited to certain types and concentrations and molecules can escape before delivery
Solution Approach 1:
The patent merges the passenger molecule with the R8 domain of the MVP protein through fusion, creating a unified structure. This combining approach ensures that the passenger molecule is an integral part of the vault particle, preventing escape during circulation and delivery, while overcoming the limitations of passive packaging regarding molecule type and concentration.
Solution Approach 2:
The patent creates a replicated structure where the passenger molecule is fused to multiple copies of the R8 domain present in the vault particle (with D39 symmetry implying multiple MVP monomers). This replication ensures consistent packaging of passenger molecules throughout the vault structure, providing both high capacity and reliable retention.
Data Source
AI summary
Disclosed herein are major vault proteins having modified R8 flexible regions, vault particles comprising major vault proteins having modified R8 flexible regions, and methods of packaging passenger polypeptides in the modified R8 flexible regions.